Average Weight Loss in Clinical Trials
Patients on Zepbound (tirzepatide) typically lose 15-21% of their body weight over 72 weeks, depending on the dose. In the SURMOUNT-1 trial, those on the 5 mg dose lost about 15% (34 pounds on average from 232 pounds starting weight), 10 mg dose lost 19.5% (41 pounds), and 15 mg dose lost 20.9% (48 pounds). These results came from adults with obesity or overweight plus comorbidities, alongside diet and exercise.[1][2]
Weight Loss by Trial and Timeline
- SURMOUNT-1 (72 weeks): Up to 21% loss vs. 3% on placebo. Half of participants hit 20% loss on highest dose.[1]
- SURMOUNT-2 (72 weeks, with type 2 diabetes): 15% loss on 15 mg vs. 3% placebo.[2]
- SURMOUNT-3 (pre-treatment phase): 21% loss after 16 weeks intensive lifestyle changes plus Zepbound, vs. 10% without.[3]
- SURMOUNT-4 (maintenance): Those staying on Zepbound kept losing (26% total), while switchers to placebo regained 15%.[3]
Loss starts quickly—about 1-2 pounds per week initially—then slows. Real-world data shows similar patterns, though individual results vary.[4]
Factors Affecting Results
Higher doses yield more loss, but adherence matters: side effects like nausea can limit dosing. Starting BMI, diet, exercise, and duration influence outcomes. Women often lose proportionally more than men. Diabetes reduces average loss by 5-6%.[2][5]
Compared to Other Weight Loss Drugs
Zepbound outperforms semaglutide (Wegovy/Ozempic). Head-to-head SURMOUNT-5 trial: 20.2% loss on Zepbound vs. 13.7% on Wegovy over 72 weeks.[6] Vs. placebo, Zepbound doubles or triples loss.
| Drug | Avg. % Loss (72 weeks) | Avg. Pounds Lost |
|------|-------------------------|------------------|
| Zepbound 15 mg | 21% | 48-52 |
| Wegovy 2.4 mg | 15% | 34-37 |
| Placebo | 2-3% | 5-7 |
What If You Stop Zepbound?
Most regain two-thirds of lost weight within a year without lifestyle changes, per SURMOUNT-4. Long-term use sustains results.[3]
Side Effects and Patient Experiences
Common issues: nausea (30%), diarrhea (20%), vomiting (10%). Serious risks include pancreatitis or thyroid tumors (rare). Patients report 10-15% loss in first 3-6 months, plateauing later. Reddit/forums note motivation from visible changes early on.[4][7]
Sources
[1]: NEJM SURMOUNT-1
[2]: NEJM SURMOUNT-2
[3]: Eli Lilly SURMOUNT-3/4
[4]: FDA Zepbound Label
[5]: JAMA Network Analysis
[6]: Lilly SURMOUNT-5
[7]: No DrugPatentWatch data; Zepbound patent expires 2036 in US. DrugPatentWatch